A healthcare operator with full appointment books and a waiting list has a growth problem that looks like a success story and behaves like a liquidity crisis. Expansion in healthcare is unusually capital-hungry: a new ambulatory surgery centre requires the shell, the fit-out, the imaging and surgical equipment, the licensing process, the payer contracting, and then a ramp period in which the facility runs at partial utilisation while carrying its full fixed cost base.
The operators who expand successfully are not the ones with the strongest clinical case. They are the ones who separate the components of the project and finance each component with the capital best suited to it — real property against real-property lenders, equipment against equipment lenders, ramp-period losses against equity, and receivables against the receivables themselves.
Separate the Real Estate from the Operating Business
The single most common structural error in healthcare expansion is funding a building with operating-company capital. A medical office building, a surgery centre shell, or a senior living property is a long-duration, income-producing real asset. Investors who buy that risk — healthcare REITs, net-lease funds, and specialist real estate credit funds — price it on the lease, the credit of the tenant, and the location. They will accept returns in the high single digits. Growth equity investors in the operating company expect multiples of their money.
Paying equity-level returns for real-estate-level risk is how operators give away the economics of their own expansion. Two structures correct this:
- Sale-leaseback: The operator sells the property to a net-lease investor and signs a long-term lease, typically fifteen to twenty years with fixed escalators. The proceeds recapitalise the operating business at a far lower effective cost than equity. The trade-off is a long-dated fixed obligation and the loss of property appreciation.
- Separate propco / opco: The property sits in a dedicated entity financed with mortgage or construction debt, and the operating company leases it. The operator retains the real estate upside and the ability to refinance the asset independently once stabilised.
Both structures require a lease that a third-party investor can underwrite. That means arm's-length rent supported by market comparables, coverage ratios the lender can test, and documentation that survives a change of control. Leases written casually between affiliated entities are routinely rejected in diligence and have to be re-papered, which costs weeks at exactly the wrong moment.
Fund the Ramp Period with Equity, Not Debt
Lenders underwrite cash flow. During the first twelve to twenty-four months of a new facility, there frequently is not any. Case volumes build as referral relationships mature, payer contracts take months to negotiate and longer to pay, and staffing must be in place before the revenue that supports it arrives.
Debt service during that window is a structural mismatch. The appropriate capital for ramp-period losses is equity or equity-like: minority growth equity, preferred equity with a deferred coupon, or an interest-only construction facility that converts to amortising debt only after a stabilisation test is met. Operators who finance ramp with amortising senior debt commonly breach a covenant in month nine of an eighteen-month ramp — not because the facility is failing, but because the instrument was wrong for the phase.
A new facility is three different risks stacked in one project. Financed as one risk, it is expensive. Financed as three, it is bankable.
Receivables Are an Asset Long Before They Are Cash
Healthcare carries a payment cycle that most other sectors would consider untenable. Claims to commercial insurers, Medicare, Medicaid and provincial health authorities are adjudicated, partially denied, appealed and eventually paid over 45 to 120 days. For a growing practice, every incremental patient widens the gap between delivered care and collected cash.
Receivables financing against insurance and government payers converts that gap into working capital without adding permanent debt or diluting ownership. Because the obligor is an insurer or a government programme rather than a small private company, the credit quality underpinning the facility is often stronger than the operator's own balance sheet — which is precisely why specialist funders will advance against it. Our overview of accounts receivable financing sets out how advance rates, reserves and dilution tests are typically structured.
Used well, a receivables facility covers payroll and supplies through the ramp, leaving scarce equity to fund the irreversible costs — construction, equipment, licensure — that nothing else will finance.
What Healthcare Investors Actually Diligence
Healthcare diligence differs from generic business diligence in ways that catch first-time raisers off guard. Investment committees in this sector concentrate on a predictable set of questions:
Payer mix and reimbursement durability
The weighted average reimbursement per procedure, the proportion of revenue from government versus commercial payers, and exposure to specific fee schedule changes. A platform with 80 per cent of revenue tied to a single payer at a single rate carries concentration risk that discounts valuation regardless of growth rate.
Regulatory and licensing posture
Certificate of need requirements where applicable, accreditation status, billing compliance history, and the corporate practice of medicine rules governing who may own what in each jurisdiction. Unresolved compliance questions are the most frequent cause of a healthcare deal dying in confirmatory diligence.
Clinician retention and dependency
How much revenue is attributable to physicians who could leave, what their employment and non-compete terms are, and whether the platform's referral base is institutional or personal. Investors pay more for systems than for individuals.
Unit economics by site
Contribution margin per facility, the ramp curve of the three most recent openings, and the capital cost per site. A credible site-level model drawn from actual openings is worth more in diligence than any projection. The documentation standards investors expect are covered in our guide to building an investor-ready data room.
Matching Capital to the Expansion Stage
The right instrument depends less on the size of the raise than on what the money does:
- Single de novo site: Construction or mortgage debt on the property, equipment finance on the capital equipment, and a modest equity or receivables layer for ramp. Equity requirement is minimised.
- Multi-site rollout: Growth equity sized for several openings plus a development line that draws per site against defined milestones, avoiding the dilution of raising the full programme cost up front.
- Acquisition of an existing practice or clinic group: Acquisition debt supported by the target's existing EBITDA, with equity covering the portion lenders will not advance and the integration cost.
- Health technology, devices and diagnostics: Venture or growth equity, because the risk is commercial adoption and regulatory clearance rather than an asset a lender can take security over.
OAKRG's healthcare capital advisory practice works with hospital groups, specialty clinics, facility developers and health technology companies to design the capital structure first and then approach the specific investors and lenders whose mandates fit each layer of it. Introductions are curated rather than broadcast, and typical transactions range from $5M to $100M+.
Common Mistakes Worth Avoiding
- Raising a single pool of equity to cover property, equipment and ramp — then discovering that two-thirds of it could have been debt.
- Signing an affiliate lease that no third-party investor will underwrite, forcing a re-paper mid-diligence.
- Taking amortising senior debt against a facility that has no cash flow for eighteen months.
- Approaching generalist investors with a healthcare deal. Payer mix, reimbursement risk and corporate practice rules require sector fluency; generalists tend to price the unfamiliar as risk.
- Beginning the raise after the construction contract is signed. The sequence should run capital structure, then committed capital, then irreversible commitments.
Facility expansion is one of the few moments when a healthcare operator's capital structure is genuinely re-set. Getting the layers right at that moment compounds for the following decade; getting them wrong is expensive to unwind.
Frequently Asked Questions
How much capital does a healthcare facility expansion require?
It varies widely by modality. A single-specialty clinic fit-out may require low single-digit millions, while a multi-operating-room ambulatory surgery centre or a senior living development commonly runs from $15M to well over $50M once land, construction, equipment and ramp-period working capital are included. The important figure is not the total but how much of it must be equity: a well-structured project pushes the majority onto real-estate debt and equipment finance, leaving equity to cover only the ramp and the costs lenders will not advance against.
Is a sale-leaseback better than a mortgage for a medical facility?
Neither is universally better. A sale-leaseback typically releases more cash than a mortgage, because it monetises the full value of the property rather than a loan-to-value percentage, and it removes the asset from the balance sheet. The cost is a long-dated fixed rent obligation and forfeited property appreciation. A mortgage retains the upside and refinancing flexibility but releases less capital and keeps the debt on the balance sheet. Operators expecting significant property appreciation or planning a sale of the whole platform usually prefer to retain ownership; operators who want maximum capital for clinical expansion more often choose the leaseback.
Can a clinic group raise capital without giving up control?
Frequently, yes. Property debt, equipment finance and receivables facilities are all non-dilutive. Where equity is required, minority growth equity of 20 to 40 per cent with protective provisions but no change of control is a common structure in the sector. Control usually passes only in a majority recapitalisation or a platform sale to a consolidator.
Why do healthcare deals fail in due diligence more often than other sectors?
Because healthcare carries two layers of risk that other sectors do not: reimbursement and regulation. Deals most often collapse over billing compliance history, unresolved licensing or certificate-of-need questions, corporate practice of medicine structures that do not survive scrutiny, or revenue concentrated in clinicians with weak employment terms. Each of these is addressable before a raise begins, and each is substantially more expensive to address after a term sheet is signed.